RT Journal
A1 Claggett B, Wei L
T1 ANalytical issues regarding rosiglitazone meta-analysis
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2011
FD January 24
VO 171
IS 2
SP 179
OP 180
DO 10.1001/archinternmed.2010.508
UL http://dx.doi.org/10.1001/archinternmed.2010.508
AB 
We read with great interest the recently published article by Nissen and Wolski,1 which updated their previous meta-analysis2 of risk for myocardial infarction and cardiovascular mortality relating to the diabetes drug rosiglitazone. The authors conclude that rosiglitazone statistically significantly increases risk of myocardial infarction relative to comparators by reporting an odds ratio of 1.28, with a 95% confidence interval (CI) of 1.02 to 1.63 and a significant P value of .04, while finding no significant difference in cardiovascular mortality (P = .86 in their current analysis, compared with P = .06 in their previous report).